BTG (NASDAQ:BTGGF) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Tuesday.

According to Zacks, “BTG plc is a healthcare company. Its operating segment consists of Interventional Medicine and Specialty Pharmaceuticals. Interventional Medicine offers treatment of cancer, severe emphysema, severe blood clots and varicoseveins. Specialty Pharmaceuticals helps patients overexposed to certain medications or toxins. BTG plc is headquartered in London, the United Kingdom. “

Shares of BTG (NASDAQ:BTGGF) remained flat at $8.64 during trading on Tuesday. BTG has a 52-week low of $6.74 and a 52-week high of $9.35. The stock has a market cap of $3.33 billion and a price-to-earnings ratio of 77.14. The stock’s 50-day moving average price is $8.55 and its 200-day moving average price is $7.64.

TRADEMARK VIOLATION WARNING: This news story was first published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another site, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this news story can be read at

Get a free copy of the Zacks research report on BTG (BTGGF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for BTG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG and related companies with's FREE daily email newsletter.